Patents by Inventor Alberto FERNANDEZ-TEJADA
Alberto FERNANDEZ-TEJADA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230219991Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.Type: ApplicationFiled: March 8, 2023Publication date: July 13, 2023Applicants: ADJUVANCE TECHNOLOGIES, INC., MEMORIAL SLOAN KETTERING CANCER CENTERInventors: David Y. GIN, Eric CHEA, Alberto FERNANDEZ-TEJADA, Jeffrey GARDNER, Jason LEWIS, Philip LIVINGSTON, J. Tyler MARTIN, Lars NORDSTROEM, Naga Vara Kishore PILLARSETTY, Govind RAGUPATHI, Derek TAN
-
Publication number: 20230131867Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.Type: ApplicationFiled: September 19, 2022Publication date: April 27, 2023Inventors: David GIN, Michelle ADAMS, Kai DENG, Philip LIVINGSTON, Govindaswami RAGUPATHI, Eric CHEA, Alberto FERNANDEZ-TEJADA, Lars Ulrik NORDSTROEM, William WALKOWICZ, Jeffrey GARDNER, Derek TAN
-
Patent number: 11629162Abstract: A number of triterpene saponin variants with different modifications on their central glycosyl ester linkage are described. Also described are methods of making and method of using such triterpene saponin variants.Type: GrantFiled: December 19, 2016Date of Patent: April 18, 2023Assignee: Memorial Sloan-Kettering Cancer CenterInventors: Derek S. Tan, David Y. Gin, William E. Walkowicz, Alberto Fernandez-Tejada, Govindaswami Ragupathi
-
Publication number: 20230026100Abstract: Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind glycosylated forms of MUC16, a tethered mucin protein. Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.Type: ApplicationFiled: July 14, 2021Publication date: January 26, 2023Inventors: David SPRIGGS, Alberto FERNANDEZ-TEJADA, Dharmarao THAPI
-
Patent number: 11447515Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.Type: GrantFiled: June 16, 2017Date of Patent: September 20, 2022Assignee: SLOAN KETTERING INSTITUTE FOR CANCER RESEARCHInventors: David Gin, Michelle Adams, Kai Deng, Philip Livingston, Govindaswami Ragupathi, Eric Chea, Alberto Fernandez-Tejada, Lars Ulrik Nordstroem, William Walkowicz, Jeffrey Gardner, Derek Tan
-
Publication number: 20220275017Abstract: Truncated triterpene saponin analogues containing a trisaccharide or tetrasaccharide ester are disclosed. Also disclosed are pharmaceutical compositions comprising truncated saponin analogues and synthetic methods of producing the truncated saponin analogues. Another aspect of the present application relates to a method for immunizing a subject, comprising administering to the subject the pharmaceutical composition comprising a minimal saponin analogue and an antigen.Type: ApplicationFiled: March 14, 2022Publication date: September 1, 2022Inventors: David Y. GIN, Eric K. CHEA, Alberto FERNANDEZ-TEJADA, Derek S. TAN, Jason S. LEWIS, Jeffrey R. GARDNER, NagaVaraKishore PILLARSETTY
-
Patent number: 11274116Abstract: Truncated triterpene saponin analogues containing a trisaccharide or tetrasaccharide ester are disclosed. Also disclosed are pharmaceutical compositions comprising truncated saponin analogues and synthetic methods of producing the truncated saponin analogues. Another aspect of the present application relates to a method for immunizing a subject, comprising administering to the subject the pharmaceutical composition comprising a minimal saponin analogue and an antigen.Type: GrantFiled: April 20, 2020Date of Patent: March 15, 2022Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: David Y. Gin, Eric K. Chea, Alberto Fernandez-Tejada, Derek S. Tan, Jason S. Lewis, Jeffrey R. Gardner, NagaVarakishore Pillarsetty
-
Patent number: 11066480Abstract: Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind glycosylated forms of MUC16, a tethered mucin protein. Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.Type: GrantFiled: March 16, 2016Date of Patent: July 20, 2021Assignee: MEMORIAL SLOAN KETTERING CANCER CENTERInventors: David Spriggs, Alberto Fernandez-Tejada, Dharmarao Thapi
-
Publication number: 20210070796Abstract: Truncated triterpene saponin analogues containing a trisaccharide or tetrasaccharide ester are disclosed. Also disclosed are pharmaceutical compositions comprising truncated saponin analogues and synthetic methods of producing the truncated saponin analogues. Another aspect of the present application relates to a method for immunizing a subject, comprising administering to the subject the pharmaceutical composition comprising a minimal saponin analogue and an antigen.Type: ApplicationFiled: April 20, 2020Publication date: March 11, 2021Inventors: David Y. Gin, Eric K. Chea, Alberto Fernandez-Tejada, Derek S. Tan, Jason S. Lewis, Jeffrey R. Gardner, NagaVaraKishore Pillarsetty
-
Patent number: 10906926Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.Type: GrantFiled: March 23, 2020Date of Patent: February 2, 2021Assignees: ADJUVANCE TECHNOLOGIES, INC., MEMORIAL SLOAN KETTERING CANCERInventors: David Y. Gin, Eric Chea, Alberto Fernandez-Tejada, Jeffrey Gardner, Jason Lewis, Philip Livingston, J. Tyler Martin, Lars Nordstroem, Naga Vara Kishore Pillarsetty, Govind Ragupathi, Derek Tan
-
Publication number: 20210002316Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.Type: ApplicationFiled: August 27, 2020Publication date: January 7, 2021Applicants: ADJUVANCE TECHNOLOGIES, INC., MEMORIAL SLOAN KETTERING CANCER CENTERInventors: David Y. GIN, Eric CHEA, Alberto FERNANDEZ-TEJADA, Jeffrey GARDNER, Jason LEWIS, Philip LIVINGSTON, J. Tyler MARTIN, Lars NORDSTROEM, Naga Vara Kishore PILLARSETTY, Govind RAGUPATHI, Derek TAN
-
Publication number: 20200239509Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.Type: ApplicationFiled: March 23, 2020Publication date: July 30, 2020Applicants: ADJUVANCE TECHNOLOGIES, INC., MEMORIAL SLOAN KETTERING CANCER CENTERInventors: David Y. GIN (Deceased), Eric CHEA, Alberto FERNANDEZ-TEJADA, Jeffrey GARDNER, Jason LEWIS, Philip LIVINGSTON, J. Tyler MARTIN, Lars NORDSTROEM, Naga Vara Kishore PILLARSETTY, Govind RAGUPATHI, Derek TAN
-
Patent number: 10626137Abstract: Truncated triterpene saponin analogues containing a trisaccharide or tetrasaccharide ester are disclosed. Also disclosed are pharmaceutical compositions comprising truncated saponin analogues and synthetic methods of producing the truncated saponin analogues. Another aspect of the present application relates to a method for immunizing a subject, comprising administering to the subject the pharmaceutical composition comprising a minimal saponin analogue and an antigen.Type: GrantFiled: June 1, 2015Date of Patent: April 21, 2020Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: David Y. Gin, Eric K. Chea, Alberto Fernandez-Tejada, Derek S. Tan, Jason S. Lewis, Jeffrey R. Gardner, NagaVaraKishore Pillarsetty
-
Publication number: 20180327436Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.Type: ApplicationFiled: November 4, 2016Publication date: November 15, 2018Applicant: ADJUVANCE TECHNOLOGIES, INC.Inventors: David Y. GIN (Deceased), Eric CHEA, Alberto FERNANDEZ-TEJADA, Jeffrey GARDNER, Jason LEWIS, Philip LIVINGSTON, J. Tyler MARTIN, Lars NORDSTROEM, Naga Vara Kishore PILLARSETTY, Govind RAGUPATHI, Derek TAN
-
Publication number: 20180112008Abstract: Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind glycosylated forms of MUC16, a tethered mucin protein. Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.Type: ApplicationFiled: March 16, 2016Publication date: April 26, 2018Applicant: Memorial Sloan Kettering Cancer CenterInventors: David SPRIGGS, Alberto FERNANDEZ-TEJADA, Dharmarao THAPI
-
Publication number: 20170283450Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.Type: ApplicationFiled: June 16, 2017Publication date: October 5, 2017Inventors: David GIN, Michelle ADAMS, Kai DENG, Philip LIVINGSTON, Govindaswami RAGUPATHI, Eric CHEA, Alberto FERNANDEZ-TEJADA, Lars Ulrik NORDSTROEM, William WALKOWICZ, Jeffrey GARDNER, Derek TAN
-
Patent number: 9718850Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.Type: GrantFiled: September 24, 2014Date of Patent: August 1, 2017Assignee: MEMORIAL SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: David Gin, Michelle Adams, Kai Deng, Philip Livingston, Govindaswami Ragupathi, Eric Chea, Alberto Fernandez-Tejada, Lars Ulrik Nordstroem, William Walkowicz, Jeffrey Gardner, Derek Tan
-
Publication number: 20170096444Abstract: Truncated triterpene saponin analogues containing a trisaccharide or tetrasaccharide ester are disclosed. Also disclosed are pharmaceutical compositions comprising truncated saponin analogues and synthetic methods of producing the truncated saponin analogues. Another aspect of the present application relates to a method for immunizing a subject, comprising administering to the subject the pharmaceutical composition comprising a minimal saponin analogue and an antigen.Type: ApplicationFiled: June 1, 2015Publication date: April 6, 2017Inventors: David Y. GIN, Eric K. CHEA, Alberto FERNANDEZ-TEJADA, Derek S. TAN, Jason S. LEWIS, Jeffrey R. GARDNER, NagaVarakishore PILLARSETTY